Building a mechanistic mathematical model of hepatitis C virus entry

The mechanism by which hepatitis C virus (HCV) gains entry into cells is a complex one, involving a broad range of host proteins. Entry is a critical phase of the viral lifecycle, and a potential target for therapeutic or vaccine-mediated intervention. However, the mechanics of HCV entry remain poorly understood. Here we describe a novel computational model of viral entry, encompassing the relationship between HCV and the key host receptors CD81 and SR-B1. We conduct experiments to thoroughly quantify the influence of an increase or decrease in receptor availability upon the extent of viral entry. We use these data to build and parameterise a mathematical model, which we then validate by further experiments. Our results are consistent with sequential HCV-receptor interactions, whereby initial interaction between the HCV E2 glycoprotein and SR-B1 facilitates the accumulation CD81 receptors, leading to viral entry. However, we also demonstrate that a small minority of viruses can achieve entry in the absence of SR-B1. Our model estimates the impact of the different obstacles that viruses must surmount to achieve entry; among virus particles attaching to the cell surface, around one third of viruses accumulate sufficient CD81 receptors, of which 4–8% then complete the subsequent steps to achieve productive infection. Furthermore, we make estimates of receptor stoichiometry; in excess of 10 receptors are likely to be required to achieve viral entry. Our model provides a tool to investigate the entry characteristics of HCV variants and outlines a framework for future quantitative studies of the multi-receptor dynamics of HCV entry.

[1]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[2]  Charles M. Rice,et al.  Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants , 2009, Journal of Virology.

[3]  Klasse Pj,et al.  Molecular determinants of the ratio of inert to infectious virus particles. , 2015 .

[4]  Takeru Suzuki,et al.  Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells. , 2018, The Journal of general virology.

[5]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[6]  Jeremie Guedj,et al.  Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938 , 2014, Antiviral therapy.

[7]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[8]  Alan S. Perelson,et al.  Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate , 2012, PLoS pathogens.

[9]  Jean Dubuisson,et al.  High Density Lipoproteins Facilitate Hepatitis C Virus Entry through the Scavenger Receptor Class B Type I* , 2005, Journal of Biological Chemistry.

[10]  S. Ciesek,et al.  Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes , 2010, Journal of Virology.

[11]  James S. Owen,et al.  Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity , 2007, Journal of Virology.

[12]  J. Coffin,et al.  Binding of more than one Tva800 molecule is required for ASLV-A entry , 2011, Retrovirology.

[13]  C. Rice,et al.  Understanding the hepatitis C virus life cycle paves the way for highly effective therapies , 2013, Nature Medicine.

[14]  Ryoichi Shima,et al.  Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus , 2016, PLoS pathogens.

[15]  Stanley M. Lemon,et al.  Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step , 2011, Journal of Virology.

[16]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[17]  Peter D. Kwong,et al.  Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions , 2014, Science.

[18]  Roslyn M Bill,et al.  A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81 , 2017, Wellcome open research.

[19]  J. Ward,et al.  Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic. , 2018, The New England journal of medicine.

[20]  Hui Li,et al.  Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4 , 2015, mBio.

[21]  Harvey Alter,et al.  HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice , 2015, Gut.

[22]  Johan Neyts,et al.  The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.

[23]  Alan S. Perelson,et al.  Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes , 2014, PLoS Comput. Biol..

[24]  C. Rice,et al.  Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Eva Herrmann,et al.  The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells , 2006, Journal of Virology.

[26]  William J. Rice,et al.  Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.

[27]  Robert J. Linhardt,et al.  Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate* , 2003, Journal of Biological Chemistry.

[28]  Uwe Carl,et al.  Development of the Twin-Strep-tag® and its application for purification of recombinant proteins from cell culture supernatants. , 2013, Protein expression and purification.

[29]  R. Bartenschlager,et al.  Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses , 2006, Journal of Virology.

[30]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[31]  Frederik Graw,et al.  Modeling Viral Spread. , 2016, Annual review of virology.

[32]  N. Dixit,et al.  Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations , 2017, Proceedings of the National Academy of Sciences.

[33]  Ralf Bartenschlager,et al.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.

[34]  Narendra M. Dixit,et al.  Viral Kinetics Suggests a Reconciliation of the Disparate Observations of the Modulation of Claudin-1 Expression on Cells Exposed to Hepatitis C Virus , 2012, PloS one.

[35]  Jens Bukh,et al.  82 DELETION OF HYPERVARIABLE REGION 1 (HVR1) OF E2 FROM HCV GENOTYPES 1–6 HAS DIFFERENTIAL EFFECT ON INFECTIVITY IN VITRO AND CAUSES INCREASED SUSCEPTIBILITY TO NEUTRALIZATION , 2009 .

[36]  A. Perelson,et al.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.

[37]  Robyn L. Stanfield,et al.  Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.

[38]  A. Nicosia,et al.  Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low-Density Lipoprotein Receptor for Hepatitis C Virus , 2013, Journal of Virology.

[39]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[40]  Charles M. Rice,et al.  Role of SR-BI in HCV entry: kinetics and molecular determinants , 2009 .

[41]  Alan S. Perelson,et al.  Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing , 2012, PLoS pathogens.

[42]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[43]  Frederic D. Bushman,et al.  Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing , 2010, Journal of Virology.

[44]  A. Tarr,et al.  The past, present and future of neutralizing antibodies for hepatitis C virus , 2014, Antiviral research.

[45]  M. Marsh,et al.  The cell biology of receptor-mediated virus entry , 2011, The Journal of cell biology.

[46]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[47]  Ralf Bartenschlager,et al.  Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.

[48]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[49]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[50]  Shingo Iwami,et al.  Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments , 2017, Proceedings of the National Academy of Sciences.

[51]  C. Rice,et al.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. , 2007, Gastroenterology.

[52]  E. Settembre,et al.  Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH , 2011, EMBO reports.

[53]  Charles M. Rice,et al.  Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.

[54]  Libin Rong,et al.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.

[55]  Charles M. Rice,et al.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.

[56]  James E Crowe,et al.  Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms , 2017, Proceedings of the National Academy of Sciences.

[57]  Michael S. Diamond,et al.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I , 2016, Journal of Virology.

[58]  Jin Zhong,et al.  Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies , 2008, Journal of Virology.

[59]  Wensheng Wei,et al.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission , 2017, Journal of Virology.

[60]  Q. Ding,et al.  The impact of hepatitis C virus entry on viral tropism. , 2014, Cell host & microbe.

[61]  P. Klasse,et al.  Molecular determinants of the ratio of inert to infectious virus particles. , 2015, Progress in molecular biology and translational science.

[62]  Ron O. Dror,et al.  Crystal Structure of a Full-Length Human Tetraspanin Reveals a Cholesterol-Binding Pocket , 2016, Cell.

[63]  James E Crowe,et al.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. , 2018, Cell host & microbe.

[64]  Peter Loppnau,et al.  Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36 , 2013, Nature.

[65]  Narendra M. Dixit,et al.  Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry , 2011, PLoS Comput. Biol..

[66]  G. Randall,et al.  Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process. , 2018, Cell host & microbe.